A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
The standard Wegovy escalation The FDA-approved schedule for semaglutide (Wegovy) for chronic weight management follows five steps: Weeks 1 to 4: 0.25 mg once weekly Weeks 5 to 8: 0.5 mg once weekly Weeks 9 to 12: 1.0 mg once weekly Weeks 13 to 16: 1.7 mg once weekly Week 17 onward: 2.4 mg once weekly (maintenance) Each step lasts a minimum of four weeks
Compounded semaglutide refers to medications prepared by a compounding pharmacy for an individual patient based on a prescription from a licensed healthcare provider
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE -/- mice
Semaglutide is the active pharmaceutical ingredient that has helped thousands of people lose and maintain weight loss in combination with diet and exercise
Patients on anticoagulants should maintain consistent vitamin K intake and discuss any supplement changes with their healthcare provider
